Abstract
5148 Background: Gemcitabine inhibits the ERCC-1 mediated repair of platinum DNA adducts. Gemcitabine and carboplatin have demonstrated improved activity over carboplatin alone in platinum sensitive patients. Cisplatin and gemcitabine have demonstrated activity in platinum resistant ovarian carcinoma. Various schedules of carboplatin and gemcitabine have been studied with carboplatin either given on day 1 or day 8. Methods: We initiated a randomized trial comparing carboplatin at an AUC of 4 on day 1 with gemcitabine 800 mg/m2 on day 1 and 8 versus ½ the dose of carboplatin (an AUC of 2 on day 1 and 8) plus gemcitabine 800 mg/m2 on day 1 and 8. Results: Currently a total of 22 evaluable patients have been accrued to this protocol with a collective response rate of 50%. We have treated an additional 12 platinum resistant patients with the carboplatin Day 1 and Gemciabine Day 1 and 8 regimen with a response rate of 50% Conclusions: The combination of gemcitabine and carboplatin are active in platinum resistant ovarian and peritoneal carcinoma patients. Further accrual to this trial is necessary to assess the optimal shedule of these agents. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Lilly Oncology
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
